Photo by sharonmccutcheon from unsplash
Key Points Question Is continuing use of dexamethasone, 6 mg/d, at discharge for patients with COVID-19 who received less than 10 days of dexamethasone treatment during hospitalization associated with readmission… Click to show full abstract
Key Points Question Is continuing use of dexamethasone, 6 mg/d, at discharge for patients with COVID-19 who received less than 10 days of dexamethasone treatment during hospitalization associated with readmission or mortality after discharge? Findings In a cohort of 1164 patients with COVID-19 who received less than 10 days of dexamethasone, 6 mg/d, during hospitalization, the rate of readmission or mortality within 14 days of discharge was 9.1% among patients who continued dexamethasone treatment compared with 11.4% among patients who did not. The difference was not statistically significant. Meaning The findings of this study suggest that prescribing dexamethasone at discharge for patients hospitalized with COVID-19 who received less than 10 days of dexamethasone is not associated with a reduction in readmission or mortality.
Journal Title: JAMA Network Open
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!